{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T12:44:03Z","timestamp":1756385043330},"reference-count":14,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,5,31]]},"DOI":"10.7759\/cureus.39779","type":"journal-article","created":{"date-parts":[[2023,5,31]],"date-time":"2023-05-31T16:43:28Z","timestamp":1685551408000},"source":"Crossref","is-referenced-by-count":1,"title":["A Rare Case of Regorafenib-Induced ST-Elevation Myocardial Infarction"],"prefix":"10.7759","author":[{"given":"Sadichhya","family":"Karki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vaishali","family":"Deenadayalan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prajwal","family":"Shrestha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samriddh","family":"Dhungel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aviral","family":"Vij","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61900-X","article-title":"Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial","volume":"381","author":"Grothey A","year":"2013","unstructured":"Grothey A, Van Cutsem E, Sobrero A, et al.. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013, 381:303-12. 10.1016\/S0140-6736(12)61900-X","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61857-1","article-title":"Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial","volume":"381","author":"Demetri GD","year":"2013","unstructured":"Demetri GD, Reichardt P, Kang YK, et al.. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013, 381:295-302. 10.1016\/S0140-6736(12)61857-1","journal-title":"Lancet"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)32453-9","article-title":"Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"389","author":"Bruix J","year":"2017","unstructured":"Bruix J, Qin S, Merle P, et al.. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017, 389:56-66. 10.1016\/S0140-6736(16)32453-9","journal-title":"Lancet"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3978\/j.issn.2218-6751.2011.12.04","article-title":"Multi-targeted tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: an era of individualized therapy","volume":"1","author":"Zhou C","year":"2012","unstructured":"Zhou C. Multi-targeted tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: an era of individualized therapy. Transl Lung Cancer Res. 2012, 1:72-7. 10.3978\/j.issn.2218-6751.2011.12.04","journal-title":"Transl Lung Cancer Res"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1093\/jncics\/pkaa076","article-title":"Cardiovascular toxicity of targeted therapies for cancer: an overview of systematic reviews","volume":"4","author":"Van Leeuwen MT","year":"2020","unstructured":"Van Leeuwen MT, Luu S, Gurney H, et al.. Cardiovascular toxicity of targeted therapies for cancer: an overview of systematic reviews. JNCI Cancer Spectr. 2020, 4:pkaa076. 10.1093\/jncics\/pkaa076","journal-title":"JNCI Cancer Spectr"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.4137\/CMO.S38335","article-title":"Efficacy, safety and cost of regorafenib in patients with metastatic colorectal cancer in French clinical practice","volume":"10","author":"Calcagno F","year":"2016","unstructured":"Calcagno F, Lenoble S, Lakkis Z, et al.. Efficacy, safety and cost of regorafenib in patients with metastatic colorectal cancer in French clinical practice. Clin Med Insights Oncol. 2016, 10:59-66. 10.4137\/CMO.S38335","journal-title":"Clin Med Insights Oncol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2007.06.054","article-title":"Autocrine VEGF signaling is required for vascular homeostasis","volume":"130","author":"Lee S","year":"2007","unstructured":"Lee S, Chen TT, Barber CL, et al.. Autocrine VEGF signaling is required for vascular homeostasis. Cell. 2007, 130:691-703. 10.1016\/j.cell.2007.06.054","journal-title":"Cell"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-018-0056-z","article-title":"Cardiotoxicity with vascular endothelial growth factor inhibitor therapy","volume":"2","author":"Touyz RM","year":"2018","unstructured":"Touyz RM, Herrmann J. Cardiotoxicity with vascular endothelial growth factor inhibitor therapy. NPJ Precis Oncol. 2018, 2:13. 10.1038\/s41698-018-0056-z","journal-title":"NPJ Precis Oncol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2011.058776","article-title":"Clinical cardiac safety profile of nilotinib","volume":"97","author":"Kim TD","year":"2012","unstructured":"Kim TD, le Coutre P, Schwarz M, et al.. Clinical cardiac safety profile of nilotinib. Haematologica. 2012, 97:883-9. 10.3324\/haematol.2011.058776","journal-title":"Haematologica"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000012705","article-title":"Risk of regorafenib-induced cardiovascular events in patients with solid tumors: a systematic review and meta-analysis","volume":"97","author":"Chen J","year":"2018","unstructured":"Chen J, Wang J. Risk of regorafenib-induced cardiovascular events in patients with solid tumors: a systematic review and meta-analysis. Medicine (Baltimore). 2018, 97:e12705. 10.1097\/MD.0000000000012705","journal-title":"Medicine (Baltimore)"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1080\/02841860903229124","article-title":"Cardiotoxicity induced by tyrosine kinase inhibitors","volume":"48","author":"Orphanos GS","year":"2009","unstructured":"Orphanos GS, Ioannidis GN, Ardavanis AG. Cardiotoxicity induced by tyrosine kinase inhibitors. Acta Oncol. 2009, 48:964-70. 10.1080\/02841860903229124","journal-title":"Acta Oncol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.00891","article-title":"A comprehensive review of clinical cardiotoxicity incidence of FDA-approved small-molecule kinase inhibitors","volume":"11","author":"Jin Y","year":"2020","unstructured":"Jin Y, Xu Z, Yan H, He Q, Yang X, Luo P. A comprehensive review of clinical cardiotoxicity incidence of FDA-approved small-molecule kinase inhibitors. Front Pharmacol. 2020, 11:891. 10.3389\/fphar.2020.00891","journal-title":"Front Pharmacol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.toxlet.2020.11.003","article-title":"Extended regorafenib treatment can be linked with mitochondrial damage leading to cardiotoxicity","volume":"336","author":"Boran T","year":"2021","unstructured":"Boran T, Akyildiz AG, Jannuzzi AT, Alpertunga B. Extended regorafenib treatment can be linked with mitochondrial damage leading to cardiotoxicity. Toxicol Lett. 2021, 336:39-49. 10.1016\/j.toxlet.2020.11.003","journal-title":"Toxicol Lett"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.6515\/acs20150629b","article-title":"Regorafenib-related myocardial injury during atrial fibrillation","volume":"32","author":"Hsiao FC","year":"2016","unstructured":"Hsiao FC, Yeh CN, Chu PH. Regorafenib-related myocardial injury during atrial fibrillation. Acta Cardiol Sin. 2016, 32:243-6. 10.6515\/acs20150629b","journal-title":"Acta Cardiol Sin"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/152297-a-rare-case-of-regorafenib-induced-st-elevation-myocardial-infarction","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:03:57Z","timestamp":1707509037000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/152297-a-rare-case-of-regorafenib-induced-st-elevation-myocardial-infarction"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,31]]},"references-count":14,"URL":"https:\/\/doi.org\/10.7759\/cureus.39779","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5,31]]}}}